Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Cityblock Acquires Homeward and Secures $116M to Unify Urban-Rural Care

    20. August 2026

    Baxter hires CFO from Smith & Nephew

    20. August 2026

    Vitestro secures FDA nod for robotic blood draw device

    20. August 2026
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»GLP-1 Patients Missed Over $10M in Savings in a Single Quarter
    News

    GLP-1 Patients Missed Over $10M in Savings in a Single Quarter

    HealthradarBy Healthradar24. Juni 2025Keine Kommentare2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    GLP-1 Patients Missed Over M in Savings in a Single Quarter
    Share
    Facebook Twitter LinkedIn Pinterest Email


    What You Should Know: 

    – A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications.

    – The analysis of over 100,000 prescriptions highlights a significant gap in cost transparency and access to savings programs, contributing to the high cost of these drugs for millions of Americans.

    A Widespread Problem with a Simple Solution

    The analysis focused on 102,166 prescriptions for manufacturer brands like Mounjaro, Ozempic, and Zepbound. It evaluated whether each prescription was eligible for additional savings through different pharmacies or via manufacturer cost-saving programs.

    The findings were clear: the vast majority of patients are overpaying. The potential savings would have come from three key areas:

    1. Giving patients transparent pharmacy pricing information.
    2. Letting patients choose their pharmacy or dispensing option.
    3. Utilizing manufacturer cost-savings programs.

    The bulk of the potential savings—a massive $7M—would have come directly from manufacturer cost-savings programs, which many patients are simply unaware of.

    The High Cost of Non-Adherence

    With 1 in 8 American adults having reported using a GLP-1, and cost being the top reason why 33% of Americans don’t fill their prescriptions, these missed savings have a direct impact on medication adherence and health outcomes. Out-of-pocket drug spending is on the rise, increasing by 25% over the last five years to $98 billion in 2024.

    GLP-1 medication adherence is particularly low, with just 46.3% of users still on the medication after 180 days. Savings programs are a critical component to improving adherence, not just for one-time use but on a recurring basis.

    “Regardless of their insurance status, the vast majority of patients are still unaware of cost saving programs,” said Josh Weiner, CEO of DoseSpot. “Patients need to do their homework – a quick online search for these programs can yield significant savings. Patients also need to speak with providers about pharmacy pricing and dispensing options – providers can access these details, but most don’t share it proactively – you need to ask.”



    Source link

    10M GLP-1 GLP1 Missed patients Quarter Savings Single
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleNew Report Untangles the Complex Regulation of Health AI Tools
    Next Article Illumina to buy SomaLogic for up to $425M
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Cityblock Acquires Homeward and Secures $116M to Unify Urban-Rural Care

    20. August 2026
    News

    Baxter hires CFO from Smith & Nephew

    20. August 2026
    News

    Vitestro secures FDA nod for robotic blood draw device

    20. August 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Marvel’s Dyasonic: A Superhero Powered by Sound—and Diabetes Tech

    13. Juni 2025531 Views

    Tombot Secures $6.1M to Bring Lifelike Robotic Puppy to Seniors with Dementia –

    19. Juni 2025500 Views

    Luna ring review | TechRadar

    26. Dezember 2025167 Views

    Hims & Hers Acquires Australian Digital Health Eucalyptus for Up to $1.15B

    20. Februar 2026159 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Marvel’s Dyasonic: A Superhero Powered by Sound—and Diabetes Tech

    13. Juni 2025531 Views

    Tombot Secures $6.1M to Bring Lifelike Robotic Puppy to Seniors with Dementia –

    19. Juni 2025500 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.